









Markets
/
Stocks
/
nasdaq-orka
/

Oruka Therapeutics Inc

ORKA

16.580USD

+0.370+2.28%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

620.93MMarket Cap

LossP/E TTM



Oruka Therapeutics Inc

16.580

+0.370+2.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

70 / 506

Overall Ranking

170 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Strong Buy

Current Rating

43.143

Target Price

+166.15%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 743.48.

Undervalued

The company’s latest PE is -7.55, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 34.13M shares, decreasing 1.09% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.82M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 5.81, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.81

Change



Financials

3.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -7.38, which is -69.17% below the recent high of -2.27 and 58.46% above the recent low of -3.06.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 70/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 9.20, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Oruka Therapeutics Inc is 44.00, with a high of 47.00 and a low of 26.00.

Score

Industry at a Glance

Previous score

9.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Strong Buy

Current Rating

43.143

Target Price

+166.15%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Oruka Therapeutics Inc

ORKA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 7.27, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 18.44 and the support level at 14.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.27

Change

0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.025

Buy

RSI(14)

59.729

Neutral

STOCH(KDJ)(9,3,3)

40.961

Neutral

ATR(14)

1.175

High Vlolatility

CCI(14)

120.696

Buy

Williams %R

49.357

Neutral

TRIX(12,20)

0.368

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

15.670

Buy

MA10

15.847

Buy

MA20

15.462

Buy

MA50

14.768

Buy

MA100

13.046

Buy

MA200

13.388

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 91.17%, representing a quarter-over-quarter increase of 2.90%. The largest institutional shareholder is The Vanguard, holding a total of 1.82M shares, representing 4.85% of shares outstanding, with 5.44% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

5.56M

-0.01%

VR Adviser, LLC

4.15M

Fairmount Funds Management LLC

3.37M

RTW Investments L.P.

1.95M

-5.47%

Deep Track Capital LP

1.90M

+31.29%

BlackRock Institutional Trust Company, N.A.

729.14K

-0.72%

The Vanguard Group, Inc.

Star Investors

1.64M

+1.66%

Braidwell LP

1.57M

+37.01%

Commodore Capital LP

1.42M

Klein (Lawrence Otto)

1.10M

+29.17%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.04, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.